{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:36:31Z","timestamp":1783632991364,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-022-01805-7","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:13:58Z","timestamp":1653326038000},"page":"1683-1688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of baseline body mass index on the outcomes of patients with\u00a0neuroendocrine neoplasms"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"O.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Morrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"issue":"2","key":"1805_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2):153\u2013171","journal-title":"Neuroendocrinology"},{"issue":"12","key":"1805_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991\u20131002","journal-title":"Neoplasia"},{"issue":"7","key":"1805_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A et al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up<sup>\u2020<\/sup>. Ann Oncol 31(7):844\u2013860","journal-title":"Ann Oncol"},{"issue":"4","key":"1805_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das S, Dasari A (2021) Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep 23(4):43","journal-title":"Curr Oncol Rep"},{"issue":"18","key":"1805_CR5","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063\u20133072","journal-title":"J Clin Oncol"},{"issue":"30","key":"1805_CR6","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.2217\/fon-2019-0292","volume":"15","author":"O Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman O (2019) Prediagnostic BMI and thyroid cancer incidence in the PLCO trial. Future Oncol 15(30):3451\u20133456","journal-title":"Future Oncol"},{"issue":"10","key":"1805_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/17476348.2019.1656532","volume":"13","author":"O Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman O (2019) Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. Expert Rev Respir Med 13(10):1029\u20131035","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"1805_CR8","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/j.clcc.2019.07.005","volume":"18","author":"O Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman O (2019) Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of 5 randomized trials. Clin Colorectal Cancer 18(4):e385\u2013e393","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"1805_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/annonc\/mdv505","volume":"27","author":"E Leoncini","year":"2016","unstructured":"Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G (2016) Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol 27(1):68\u201381","journal-title":"Ann Oncol"},{"issue":"9","key":"1805_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","volume":"18","author":"H Lennon","year":"2016","unstructured":"Lennon H, Sperrin M, Badrick E, Renehan AG (2016) The obesity paradox in cancer: a review. Curr Oncol Rep 18(9):56","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1805_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13668-019-00280-6","volume":"8","author":"DH Lee","year":"2019","unstructured":"Lee DH, Giovannucci EL (2019) The obesity paradox in cancer: epidemiologic insights and perspectives. Curr Nutr Rep 8(3):175\u2013181","journal-title":"Curr Nutr Rep"},{"key":"1805_CR12","first-page":"1309","volume":"20","author":"E Glazer","year":"2014","unstructured":"Glazer E, Stanko K, Ong E, Guerrero M (2014) Decreased inpatient mortality in obese patients with abdominal nets. Endocr Pract 20:1309\u20131314","journal-title":"Endocr Pract"},{"issue":"2","key":"1805_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11154-018-9466-z","volume":"19","author":"B Altieri","year":"2018","unstructured":"Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A et al (2018) Nutrition and neuroendocrine tumors: an update of the literature. Rev Endocr Metab Disord 19(2):159\u2013167","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"1805_CR14","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/nu10121854","volume":"10","author":"L Barrea","year":"2018","unstructured":"Barrea L, Altieri B, Muscogiuri G, Laudisio D, Annunziata G, Colao A et al (2018) Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness. Nutrients 10(12):1854","journal-title":"Nutrients"},{"issue":"1","key":"1805_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-020-07506-9","volume":"20","author":"JB Wang","year":"2020","unstructured":"Wang JB, Xue Z, Lu J, He QL, Zheng ZF, Xu BB et al (2020) Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. BMC Cancer 20(1):1002","journal-title":"BMC Cancer"},{"issue":"30","key":"1805_CR16","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.3748\/wjg.v26.i30.4537","volume":"26","author":"MS Khan","year":"2020","unstructured":"Khan MS, Walter T, Buchanan-Hughes A, Worthington E, Keeber L, Feuilly M et al (2020) Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: a systematic review. World J Gastroenterol 26(30):4537\u20134556","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1805_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000503634","volume":"110","author":"E Laing","year":"2020","unstructured":"Laing E, Kiss N, Michael M, Krishnasamy M (2020) Nutritional complications and the management of patients with gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 110(5):430\u2013442","journal-title":"Neuroendocrinology"},{"issue":"7","key":"1805_CR18","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/nu12071961","volume":"12","author":"J Kikut","year":"2020","unstructured":"Kikut J, Jasi\u0144ska A, Pob\u0142ocki J, Brodowski J, Ma\u0142gorzata S (2020) Assessment and state of nutrition of patients with gastroenteropancreatic neuroendocrine neoplasms. Nutrients 12(7):1961","journal-title":"Nutrients"},{"issue":"4","key":"1805_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s11154-020-09597-y","volume":"22","author":"M Gallo","year":"2021","unstructured":"Gallo M, Adinolfi V, Barucca V, Prinzi N, Renzelli V, Barrea L et al (2021) Expected and paradoxical effects of obesity on cancer treatment response. Rev Endocr Metab Disord 22(4):681\u2013702","journal-title":"Rev Endocr Metab Disord"},{"key":"1805_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649496","volume":"12","author":"L Barrea","year":"2021","unstructured":"Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R et al (2021) Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne) 12:649496","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1805_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12020-021-02869-w","volume":"75","author":"B Altieri","year":"2022","unstructured":"Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G et al (2022) Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. Endocrine 75(2):623\u2013634","journal-title":"Endocrine"},{"issue":"1","key":"1805_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12967-021-03010-1","volume":"19","author":"L Barrea","year":"2021","unstructured":"Barrea L, Muscogiuri G, Pugliese G, Modica R, Laudisio D, Aprano S et al (2021) Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? J Transl Med 19(1):324","journal-title":"J Transl Med"},{"issue":"2","key":"1805_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40519-018-0489-y","volume":"23","author":"I Trestini","year":"2018","unstructured":"Trestini I, Carbognin L, Bonaiuto C, Tortora G, Bria E (2018) The obesity paradox in cancer: clinical insights and perspectives. Eat Weight Disord 23(2):185\u2013193","journal-title":"Eat Weight Disord"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01805-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:10:57Z","timestamp":1659960657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01805-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01805-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OA: advisory boards with Roche, Eisai, Lilly, Ipsen, Amgen,\u00a0and Bayer. SG: none, DM: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was approved by the Health Research Ethics Board of Alberta (HREBA.CC-20-0217). Given the retrospective nature of data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by the ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}